



UCB Extraordinary General Meeting

Brussels, Belgium, 6 November, 2009 – 18:00 (CET) – regulated information –

Following the successful placement of its senior unsecured convertible bonds, due 2015 (the 'Bonds') on 30 September 2009, an extraordinary general shareholders' meeting was held earlier today by the company.

All proposed resolutions that were submitted to the extraordinary general shareholders' meeting were approved, including all resolutions related to the recent bond issues and the appointment of a new board member.

For further information

Richard Simpson, Investor Relations, UCB
T +32.2.559.9494, richard.simpson@ucb.com

Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712, michael.tuck-sherman@ucb.com

Nancy Nackaerts, External Communications, UCB
M: +32 473 86 44 14, nancy.nackaerts@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a biopharmaceutical company dedicated to the research, development and commercialization of innovative medicines with a focus on the fields of central nervous system and immunology disorders. Employing approximately 10,000 people in over 40 countries, UCB generated revenue of EUR 3.6 billion in 2008. UCB is listed on Euronext Brussels (symbol: UCB).

Forward-looking statements

This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.